Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189)
Hong Kong · Delayed Price · Currency is HKD 0.1510
+0.0290 (23.77%)
Jun 1, 2026, 3:58 PM HKT
HKG:8189 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 522.97 | 385.48 | 398 | 403.73 | 476.38 | |
Revenue Growth (YoY) | 35.67% | -3.15% | -1.42% | -15.25% | 28.98% |
Cost of Revenue | 552.36 | 368.51 | 376.63 | 388.91 | 430.78 |
Gross Profit | -29.4 | 16.97 | 21.37 | 14.82 | 45.6 |
Selling, General & Admin | 32.22 | 34.26 | 29.91 | 33.21 | 48.76 |
Research & Development | 4.14 | 1.1 | 1.32 | 1.14 | 3.5 |
Operating Expenses | 38.28 | 45.35 | 40.7 | 39.24 | 63.99 |
Operating Income | -67.68 | -28.38 | -19.34 | -24.41 | -18.39 |
Interest Expense | -3.79 | -4.58 | -5.17 | -6.4 | -5.47 |
Interest & Investment Income | 0.08 | 0.05 | 0.25 | 0.76 | 0.43 |
Earnings From Equity Investments | -0 | - | - | - | 1 |
Currency Exchange Gain (Loss) | - | - | - | - | 0.08 |
Other Non Operating Income (Expenses) | -12.74 | -2.6 | -2 | 0.09 | -0.38 |
EBT Excluding Unusual Items | -84.13 | -35.52 | -26.26 | -29.97 | -22.73 |
Impairment of Goodwill | - | - | - | - | -0.42 |
Gain (Loss) on Sale of Investments | 2.6 | - | 0 | 5.96 | - |
Gain (Loss) on Sale of Assets | -8.23 | -0.28 | -0.2 | -0.05 | 0.15 |
Asset Writedown | -23.97 | -2.41 | - | - | -21.84 |
Other Unusual Items | 0.79 | - | 14.44 | - | - |
Pretax Income | -112.94 | -38.21 | -12.01 | -24.06 | -44.84 |
Income Tax Expense | 0.61 | -0.22 | -1.04 | -0.51 | -0.05 |
Earnings From Continuing Operations | -113.54 | -37.99 | -10.97 | -23.55 | -44.78 |
Earnings From Discontinued Operations | - | 1.85 | -5.6 | -2.44 | - |
Net Income to Company | -113.54 | -36.14 | -16.57 | -25.99 | -44.78 |
Minority Interest in Earnings | 22.72 | 8.34 | -3.59 | -1.46 | 2.53 |
Net Income | -90.82 | -27.8 | -20.16 | -27.45 | -42.26 |
Net Income to Common | -90.82 | -27.8 | -20.16 | -27.45 | -42.26 |
Shares Outstanding (Basic) | 2,080 | 1,895 | 1,895 | 1,895 | 1,895 |
Shares Outstanding (Diluted) | 2,080 | 1,895 | 1,895 | 1,895 | 1,895 |
Shares Change (YoY) | 9.77% | - | - | - | - |
EPS (Basic) | -0.04 | -0.01 | -0.01 | -0.01 | -0.02 |
EPS (Diluted) | -0.04 | -0.01 | -0.01 | -0.01 | -0.02 |
Free Cash Flow | - | -28.83 | -15.62 | -21.62 | -34.28 |
Free Cash Flow Per Share | - | -0.01 | -0.01 | -0.01 | -0.02 |
Gross Margin | -5.62% | 4.40% | 5.37% | 3.67% | 9.57% |
Operating Margin | -12.94% | -7.36% | -4.86% | -6.05% | -3.86% |
Profit Margin | -17.37% | -7.21% | -5.07% | -6.80% | -8.87% |
Free Cash Flow Margin | - | -7.48% | -3.92% | -5.36% | -7.20% |
EBITDA | -60.7 | -21.41 | -10.45 | -14.82 | -14.27 |
EBITDA Margin | -11.61% | -5.55% | -2.63% | -3.67% | -3.00% |
D&A For EBITDA | 6.97 | 6.97 | 8.89 | 9.59 | 4.12 |
EBIT | -67.68 | -28.38 | -19.34 | -24.41 | -18.39 |
EBIT Margin | -12.94% | -7.36% | -4.86% | -6.05% | -3.86% |
Advertising Expenses | 1.31 | 1.2 | 0.57 | 1.02 | 2.52 |